Director/PDMR Shareholding

RNS Number : 1827I

Hikma Pharmaceuticals Plc

12 April 2022

 

Hikma Pharmaceuticals PLC

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Said Darwazah
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083
b)	Nature of the transaction	Grant of a pledge by Darhold Limited over 650,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman, who is a director and shareholder of Darhold.
c)	Price(s) and volume(s)	Price(s): £0.00p Volume(s): 650,000
d)	Aggregated information	Aggregated volume: 650,000 Price: £0.00p
e)	Date of the transaction	11 April 2022
f)	Place of the transaction	Amman

Mazen Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mazen Darwazah
2	Reason for the notification
a)	Position/status	Executive Vice Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083
b)	Nature of the transaction	Grant of a pledge by Darhold Limited over 650,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold.
c)	Price(s) and volume(s)	Price(s): £0.00p Volume(s): 650,000
d)	Aggregated information	Aggregated volume: 650,000 Price: £0.00p
e)	Date of the transaction	11 April 2022
f)	Place of the transaction	Amman

Mohammed 'Ali' Al-Husry

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mohammed 'Ali' Al-Husry
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083
b)	Nature of the transaction	Grant of a pledge by Darhold Limited over 650,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold.
c)	Price(s) and volume(s)	Price(s): £0.00p Volume(s): 650,000
d)	Aggregated information	Aggregated volume: 650,000 Price: £0.00p
e)	Date of the transaction	11 April 2022
f)	Place of the transaction	Amman

Peter Speirs
Company Secretary, responsible for releasing this announcement

12 April 2022
[phone]

 

END

 

 

DSHBLGDSCSBDGDD